PPARA and metabolic dysfunction-associated steatotic liver disease: Thus, dissecting the chromatin-level mechanisms by which BRD9 modulates PPARα target gene expression will be crucial for identifying novel therapeutic strategies for lipid metabolism disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), respectively.